Key takeaways
Brenzavvy (bexagliflozin) and Jardiance (empagliflozin) are both medications in the sodium-glucose cotransporter 2 (SGLT2) inhibitor medication class. They are used to help manage Type 2 diabetes by lowering blood sugar levels. Brenzavvy and Jardiance work by preventing sugar from being reabsorbed in the kidneys, which helps remove excess sugar through the urine. However, Jardiance (empagliflozin) has additional FDA-approved uses, including reducing the risk of heart-related complications in adults with heart failure or chronic kidney disease, while Brenzavvy (bexagliflozin) is only approved for Type 2 diabetes. Brenzavvy is typically taken as a 20 mg tablet once daily, whereas Jardiance starts at 10 mg and can be increased to 25 mg in some cases. Neither medication is available in a generic form. Common side effects for both include urinary tract infections, yeast infections, and increased urination. Both medications can increase the risk of low blood sugar and low blood pressure, especially combined with other medications that have those effects.
